riluzole has been researched along with Motor Neuron Disease in 50 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Motor Neuron Disease: Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of the drug is not a major concern." | 8.82 | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). ( Lyon, M; Miller, RG; Mitchell, JD; Moore, DH, 2003) |
| "In the wobbler mouse motor neuron disease (MND), we firstly evaluated the effect of riluzole, the only approved drug for amyotrophic lateral sclerosis, and compared it with that of brain-derived neurotrophic factor (BDNF)." | 7.72 | Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. ( Ishiyama, T; Mitsumoto, H; Nakayama, C; Nishibe, H; Okada, R, 2004) |
| "Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of the drug is not a major concern." | 4.82 | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). ( Lyon, M; Miller, RG; Mitchell, JD; Moore, DH, 2003) |
| "In the wobbler mouse motor neuron disease (MND), we firstly evaluated the effect of riluzole, the only approved drug for amyotrophic lateral sclerosis, and compared it with that of brain-derived neurotrophic factor (BDNF)." | 3.72 | Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. ( Ishiyama, T; Mitsumoto, H; Nakayama, C; Nishibe, H; Okada, R, 2004) |
| "Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depression and anxiety are reported in up to 44% and 33%, respectively." | 2.72 | A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. ( Abrahams, S; Beswick, E; Carson, A; Chandran, S; Dakin, R; Mehta, AR; Newton, J; Pal, S; Park, E; Wong, C, 2021) |
| "Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease." | 2.43 | Diagnostic investigation and multidisciplinary management in motor neuron disease. ( Fonseca, J; Mendes Ribeiro, J; Reis, C; Rocha, JA; Simões, F, 2005) |
| "In a proportion of familial amyotrophic lateral sclerosis there is a mutation in the gene encoding the enzyme copper/zinc superoxide dismutase 1; this has allowed mutation screening and generated considerable laboratory based research." | 2.41 | Management of motor neurone disease. ( Howard, RS; Orrell, RW, 2002) |
| "Amyotrophic lateral sclerosis is the most common form of motor neuron disease, in which patients demonstrate evidence of both anterior horn cell (lower motor neuron) and corticospinal tract (upper motor neuron) dysfunction." | 2.41 | Motor neuron disease. ( Jackson, CE; Rosenfeld, J, 2001) |
| "Riluzole has been approved by the National Institute for Clinical Excellence for use in the National Health Service of the United Kingdom." | 2.41 | Amyotrophic lateral sclerosis: current understanding. ( Charles, T; Swash, M, 2001) |
| "The first clinical trials in spinal muscular atrophy are currently underway." | 2.40 | Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. ( Miller, RG, 1999) |
| "Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which was thought to be untreatable for a long time." | 2.40 | Antiglutamate therapy of ALS--which is the next step? ( Ludolph, AC; Meyer, T; Riepe, MW, 1999) |
| "Therapeutic trials for amyotrophic lateral sclerosis have attracted much attention, but no drug tested has been effective yet." | 2.39 | Amyotrophic lateral sclerosis. ( Rowland, LP, 1994) |
| "Amyotrophic lateral sclerosis (ALS) is a rare and progressive neurodegenerative disease involving the upper and lower motor neurons." | 1.51 | Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model. ( Azevedo, LF; Conde, B; Winck, JC, 2019) |
| "Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease resulting in muscle weakness, dysarthria and dysphagia, and ultimately respiratory failure leading to death." | 1.48 | Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. ( Benstead, T; Briemberg, H; Genge, A; Grant, I; Hader, W; Hodgkinson, VL; Johnston, WS; Kalra, S; Korngut, L; Linassi, G; Lounsberry, J; Massie, R; Melanson, M; Mirian, A; O'Connell, C; Schellenberg, K; Shoesmith, C; Taylor, S; Worley, S; Zinman, L, 2018) |
| "The association between Amyotrophic Lateral Sclerosis or other Motor Neuron Diseases (MNDs) with Lymphoproliferative Disorders (LPDs) and plasma cell neoplasias (such as Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, multiple myeloma, chronic lymphocytic leukemia) has been described." | 1.35 | Motor neuron disease associated with multiple myeloma. ( Demirkiran, M; Koc, F; Paydas, S; Yerdelen, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.00) | 18.2507 |
| 2000's | 30 (60.00) | 29.6817 |
| 2010's | 12 (24.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, C | 2 |
| Dakin, RS | 1 |
| Williamson, J | 1 |
| Newton, J | 3 |
| Steven, M | 1 |
| Colville, S | 2 |
| Stavrou, M | 1 |
| Gregory, JM | 1 |
| Elliott, E | 1 |
| Mehta, AR | 2 |
| Chataway, J | 1 |
| Swingler, RJ | 1 |
| Parker, RA | 1 |
| Weir, CJ | 1 |
| Stallard, N | 1 |
| Parmar, MKB | 1 |
| Macleod, MR | 1 |
| Pal, S | 3 |
| Chandran, S | 3 |
| Loveland, P | 1 |
| Wong, A | 1 |
| Vivekanandam, V | 1 |
| Lim, WK | 1 |
| Beswick, E | 1 |
| Park, E | 1 |
| Dakin, R | 1 |
| Carson, A | 1 |
| Abrahams, S | 2 |
| Ilieva, H | 1 |
| Maragakis, NJ | 1 |
| Lau, FS | 1 |
| Brennan, FP | 1 |
| Gardiner, MD | 1 |
| Hodgkinson, VL | 1 |
| Lounsberry, J | 1 |
| Mirian, A | 1 |
| Genge, A | 1 |
| Benstead, T | 1 |
| Briemberg, H | 1 |
| Grant, I | 1 |
| Hader, W | 1 |
| Johnston, WS | 1 |
| Kalra, S | 1 |
| Linassi, G | 1 |
| Massie, R | 1 |
| Melanson, M | 1 |
| O'Connell, C | 1 |
| Schellenberg, K | 1 |
| Shoesmith, C | 1 |
| Taylor, S | 1 |
| Worley, S | 1 |
| Zinman, L | 1 |
| Korngut, L | 1 |
| Gorrie, GH | 1 |
| Leighton, D | 1 |
| Mcdonald, M | 1 |
| Forbes, R | 1 |
| Hair, M | 1 |
| Swingler, R | 1 |
| Conde, B | 1 |
| Winck, JC | 1 |
| Azevedo, LF | 1 |
| Smith, W | 3 |
| Burrell, JR | 1 |
| Halliday, GM | 1 |
| Kril, JJ | 1 |
| Ittner, LM | 1 |
| Götz, J | 1 |
| Kiernan, MC | 3 |
| Hodges, JR | 1 |
| Moore, A | 1 |
| Young, CA | 1 |
| Hughes, DA | 1 |
| Weiss, MD | 1 |
| Carter, GT | 1 |
| Brunet, N | 1 |
| Tarabal, O | 1 |
| Esquerda, JE | 1 |
| Calderó, J | 1 |
| Orrell, RW | 2 |
| Zoing, M | 1 |
| Kiernan, M | 1 |
| Rauf, J | 1 |
| Akhtar, J | 1 |
| Khealani, BA | 1 |
| Ali, L | 1 |
| Pascuzzi, RM | 1 |
| Howard, RS | 1 |
| Miller, RG | 3 |
| Mitchell, JD | 2 |
| Lyon, M | 1 |
| Moore, DH | 1 |
| Leigh, PN | 1 |
| Al-Chalabi, A | 1 |
| Ampong, MA | 1 |
| Goldstein, LH | 1 |
| Johnson, J | 1 |
| Lyall, R | 1 |
| Moxham, J | 1 |
| Mustfa, N | 1 |
| Rio, A | 1 |
| Shaw, C | 1 |
| Willey, E | 1 |
| Ishiyama, T | 1 |
| Okada, R | 1 |
| Nishibe, H | 1 |
| Mitsumoto, H | 1 |
| Nakayama, C | 1 |
| Henderson, RD | 1 |
| McCombe, PA | 1 |
| Pontieri, FE | 1 |
| Ricci, A | 1 |
| Pellicano, C | 1 |
| Benincasa, D | 1 |
| Buttarelli, FR | 1 |
| Williams, B | 1 |
| Rocha, JA | 1 |
| Reis, C | 1 |
| Simões, F | 1 |
| Fonseca, J | 1 |
| Mendes Ribeiro, J | 1 |
| Zoing, MC | 1 |
| Burke, D | 1 |
| Pamphlett, R | 1 |
| O'brien, MR | 1 |
| Joshi, M | 1 |
| Logroscino, G | 1 |
| Zoccolella, S | 1 |
| Koc, F | 1 |
| Paydas, S | 1 |
| Yerdelen, D | 1 |
| Demirkiran, M | 1 |
| McDermott, CJ | 1 |
| Shaw, PJ | 1 |
| Rowland, LP | 1 |
| Wokke, J | 1 |
| Bryson, HM | 1 |
| Fulton, B | 1 |
| Benfield, P | 1 |
| Reynolds, DJ | 1 |
| Ludolph, AC | 1 |
| Meyer, T | 1 |
| Riepe, MW | 1 |
| Kennel, P | 1 |
| Revah, F | 1 |
| Bohme, GA | 1 |
| Bejuit, R | 1 |
| Gallix, P | 1 |
| Stutzmann, JM | 1 |
| Imperato, A | 1 |
| Pratt, J | 1 |
| Jackson, CE | 1 |
| Rosenfeld, J | 1 |
| Sandercock, J | 2 |
| Burls, A | 2 |
| Hyde, C | 2 |
| Fry-Smith, A | 2 |
| Barton, P | 1 |
| Bryan, S | 2 |
| Stewart, A | 2 |
| Wheatley, K | 1 |
| Gray, R | 1 |
| Turner, M | 1 |
| Noth, J | 1 |
| Barnett, D | 1 |
| Charles, T | 1 |
| Swash, M | 1 |
| Barton, PM | 1 |
| Sorenson, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870] | Phase 2/Phase 3 | 800 participants (Anticipated) | Interventional | 2020-02-27 | Recruiting | ||
| A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe[NCT02290886] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
23 reviews available for riluzole and Motor Neuron Disease
| Article | Year |
|---|---|
A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Cognition; Humans; Motor Neuron Disease; Quality of Life; Riluzole | 2021 |
Motoneuron Disease: Clinical.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Exercise Therapy; Frontotemporal Dementia; Genet | 2017 |
The frontotemporal dementia-motor neuron disease continuum.
Topics: Activities of Daily Living; Brain; C9orf72 Protein; Cognition; DNA Methylation; DNA Repeat Expansion | 2016 |
Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.
Topics: Costs and Cost Analysis; Disease Progression; Humans; Markov Chains; Models, Economic; Motor Neuron | 2017 |
Motor neuron disease: systematic reviews of treatment for ALS and SMA.
Topics: Amyotrophic Lateral Sclerosis; Databases as Topic; Humans; Motor Neuron Disease; Muscular Atrophy, S | 2010 |
ALS, motor neuron disease, and related disorders: a personal approach to diagnosis and management.
Topics: Adolescent; Adult; Animals; Case Management; Combined Modality Therapy; Creatine; Diagnosis, Differe | 2002 |
Management of motor neurone disease.
Topics: Deglutition Disorders; Humans; Motor Neuron Disease; Neuroprotective Agents; Palliative Care; Respir | 2002 |
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Topics: Adult; Amyotrophic Lateral Sclerosis; Databases as Topic; Double-Blind Method; Drug Evaluation; Huma | 2003 |
The management of motor neurone disease.
Topics: Gastrostomy; Genetic Counseling; Humans; Motor Neuron Disease; Neuroprotective Agents; Respiration, | 2003 |
Diagnostic investigation and multidisciplinary management in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Bulbar Palsy, Progressive; Diagnosis, Differential; Diagnostic Imagin | 2005 |
Audit of outcomes in motor neuron disease (MND) patients treated with riluzole.
Topics: Female; Humans; Male; Medical Audit; Middle Aged; Motor Neuron Disease; Neuroprotective Agents; Rilu | 2006 |
Diagnosis and management of motor neurone disease.
Topics: Antioxidants; Diagnosis, Differential; Humans; Motor Neuron Disease; Neuroprotective Agents; Physici | 2008 |
Amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Excitatory Amino Acid Antagonists; Humans; | 1994 |
Riluzole.
Topics: Amyotrophic Lateral Sclerosis; Animals; Drug Interactions; Female; Humans; Male; Middle Aged; Motor | 1996 |
Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind | 1996 |
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.
Topics: Acetates; Adolescent; Adult; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrop | 1999 |
Antiglutamate therapy of ALS--which is the next step?
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Forecasting; Humans; Mice; Mice, Tr | 1999 |
Motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy | 2001 |
The treatment of motor neurone disease.
Topics: Analgesics; Enteral Nutrition; Humans; Motor Neuron Disease; Neuroprotective Agents; Patient Care Ma | 2001 |
Examining the evidence about treatment in ALS/MND.
Topics: Clinical Trials as Topic; Critical Care; Excitatory Amino Acid Antagonists; Humans; Motor Neuron Dis | 2001 |
Amyotrophic lateral sclerosis: current understanding.
Topics: Drug Approval; England; Humans; Motor Neuron Disease; Riluzole; Risk Factors | 2001 |
The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
Topics: Cost-Benefit Analysis; Humans; Incidence; Motor Neuron Disease; Neuroprotective Agents; Prevalence; | 2001 |
Emerging strategies for drug development in motor neuron disease.
Topics: Animals; Drug Design; Excitatory Amino Acid Antagonists; Humans; Motor Neuron Disease; Riluzole; Sup | 2002 |
3 trials available for riluzole and Motor Neuron Disease
| Article | Year |
|---|---|
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode | 2022 |
Minocycline in amyotrophic lateral sclerosis: a pilot study.
Topics: Anticonvulsants; Drug Therapy, Combination; Humans; Minocycline; Motor Neuron Disease; Pilot Project | 2005 |
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002).
Topics: Adult; Aged; Australia; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motor Neuron Disease; | 2006 |
24 other studies available for riluzole and Motor Neuron Disease
| Article | Year |
|---|---|
Subacute combined degeneration of the spinal cord masking motor neuron disease: a case report.
Topics: Comorbidity; Confusion; Diagnosis, Differential; Disease Progression; Dysarthria; Electromyography; | 2019 |
Multidisciplinary management of motor neurone disease.
Topics: Dyspnea; Humans; Interdisciplinary Communication; Motor Neuron Disease; Muscle Spasticity; Neuroprot | 2018 |
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Excitatory Amino Acid Antagonists; | 2018 |
Improved survival and 30-day mortality after gastrostomy in Scottish motor neurone disease patients: evidence from a national retrospective cohort study using STROBE criteria.
Topics: Adult; Amyotrophic Lateral Sclerosis; Cohort Studies; Enteral Nutrition; Female; Gastrostomy; Humans | 2019 |
Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Bayes Theorem; Female; Humans; Male; | 2019 |
Rilutek now subsidised.
Topics: Financing, Government; Humans; Motor Neuron Disease; Neuroprotective Agents; New Zealand; Riluzole | 2013 |
Preface: the state of the science of all motor neuron diseases.
Topics: Amyotrophic Lateral Sclerosis; Biomedical Research; Humans; Incidence; Motor Neuron Disease; Neuropr | 2008 |
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord.
Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Easier access to motor neurone drug.
Topics: Drug Costs; Financing, Government; Humans; Motor Neuron Disease; Neuroprotective Agents; New Zealand | 2004 |
Motor neurone disease - caring for the patient in general practice.
Topics: Australia; Deglutition Disorders; Disease Progression; Electrophysiology; General Practice; Humans; | 2011 |
Peripheral (limb) myokymic discharges in motor neuron disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Baclofen; Deltoid Muscle; Directive | 2012 |
Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease.
Topics: Animals; Disease Progression; Female; Mice; Mice, Neurologic Mutants; Motor Neuron Disease; Neuromus | 2004 |
Riluzole: a glimmer of hope in the treatment of motor neurone disease.
Topics: Clinical Trials as Topic; Humans; Motor Neuron Disease; Neuroprotective Agents; Riluzole | 2005 |
Riluzole: a glimmer of hope in the treatment of motor neurone disease.
Topics: Chemical and Drug Induced Liver Injury; Drug Interactions; Humans; Male; Middle Aged; Motor Neuron D | 2005 |
Access to palliative care for people with motor neurone disease in New Zealand: a patient's perspective.
Topics: Australia; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Motor Neuro | 2005 |
Rilutek should be subsidised.
Topics: Drug and Narcotic Control; Financing, Government; Humans; Motor Neuron Disease; National Health Prog | 2005 |
Efficacy of riluzole: who are the patients enrolled in the studies?
Topics: Female; Humans; Male; Medical Audit; Middle Aged; Motor Neuron Disease; Neuroprotective Agents; Pati | 2007 |
Motor neuron disease associated with multiple myeloma.
Topics: Aged; Fatal Outcome; Humans; Male; Motor Neuron Disease; Multiple Myeloma; Neuroprotective Agents; R | 2008 |
Riluzole.
Topics: Humans; Motor Neuron Disease; Neuroprotective Agents; Prognosis; Riluzole; Thiazoles | 1996 |
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn).
Topics: Animals; Body Weight; Disease Models, Animal; Hand Strength; Mice; Mice, Transgenic; Motor Neuron Di | 2000 |
Riluzole for motor neurone disease. More trials are needed.
Topics: Clinical Trials as Topic; Drug Approval; Humans; Motor Neuron Disease; Neuroprotective Agents; Riluz | 2001 |
Riluzole for motor neurone disease. Large, more economical trial is needed.
Topics: Clinical Trials as Topic; Drug Approval; Drug Costs; Evidence-Based Medicine; Humans; Motor Neuron D | 2001 |
[Amyotrophic lateral sclerosis].
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Anticonvulsants; Female; Humans; Incidence; Male; Motor | 2001 |
Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE.
Topics: Evidence-Based Medicine; Humans; Motor Neuron Disease; Neuroprotective Agents; Riluzole; United King | 2001 |